Abstract Category: Interventional Cardiology Presentation Number: Authors: Laura Mauri, Martin Leon, Donald Cutlip, Jeffrey Popma, Peter Fitzgerald, Joseph Massaro, Alan Yeung, Brigham and Women's Hospital, Boston, MA, USA, Stanford University Medical Center, Palo Alto, CA, USA Background: The Resolute zotarolimus-eluting stent (R-ZES) was developed to allow sustained release of zotarolimus to inhibit neointimal hyperplasia after treatment of coronary stenosis, while preserving efficacy. R-ZES has been prospectively studied in 5130 patients enrolled in 5 trials of the RESOLUTE Global Clinical Program (RESOLUTE First-in-Man; All Comers [RAC]; International [RINT]; Japan and US), all with similar endpoint definition and adjudication. RAC was a randomized trial demonstrating non-inferiority of the R-ZES in comparison to the control everolimus-eluting stent. The RESOLUTE US (RUS) trial provides a larger cohort of subjects treated with R-ZES specifically with indications under consideration for FDA approval, and consists of a large Main Study cohort and 2 smaller studies of 2.25 and 4.0 mm stent sizes, and is currently in long term follow-up.
